Curaleaf Q2 2026 revenue rises 10% as wholesale growth offsets price pressure, company says

• Curaleaf posted Q2 revenue of US$ 340.1 million, up 10%, driven by retail footprint expansion, international patient growth, new wholesale partnerships.
• Retail revenue rose 5% to US$ 240.7 million, led by new store openings; pricing pressure and tougher competition offset gains.
• Wholesale revenue increased 21% to US$ 96 million, supported by expanded partner distribution; international results benefited from the QMID device launch.
• Gross profit climbed to US$ 169.9 million; margin improved to 50% as mix shifted, despite higher cost of goods sold tied to faster wholesale growth.
• Operating expenses rose 13% to US$ 165.7 million on higher compensation, lobbying and public relations, branding and marketing, pushing operating income down to US$ 4.2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.